Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-06-08 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2010-06-08 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, a foreign private issuer, with the SEC. It is titled as an "Investor Relations Release" and primarily discusses clinical trial results for the drug Afinitor (everolimus) related to tuberous sclerosis and brain tumors. The document includes detailed study results, safety information, and regulatory submission updates. It is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information to investors about clinical trial outcomes and regulatory progress. The document length is about 15,000 characters, indicating it is a substantive announcement but not a full financial report. There is no indication it is a proxy, governance, or capital structure update. The Form 6-K is a standard SEC filing for foreign private issuers to disclose material information. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like earnings release or annual report.
2010-06-08 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release detailing clinical trial results and drug information, specifically about the drug Zometa and its benefits in cancer treatment. There are no financial statements, comprehensive financial performance data, or detailed management analysis typical of annual or interim reports. The document is not a transcript, audit report, or governance information. It is a regulatory filing that provides material information to investors but does not fit into more specific categories like earnings release or capital update. Given the nature of Form 6-K filings and the content, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2010-06-08 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing new clinical data results for the drug Tasigna compared to Glivec, including study details, safety information, and regulatory status updates. It is not a full financial report, audit report, earnings release, or management discussion. It is a regulatory announcement providing material information to investors about clinical trial results and regulatory filings. The document length is 15,000 characters, which is substantial but the content is primarily a press release style update rather than a detailed financial or management report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2010-06-04 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains an investor relations release announcing the positive results of a Phase III clinical trial (RADIANT-3) for the drug Afinitor (everolimus) in treating advanced pancreatic neuroendocrine tumors. The document is primarily a regulatory announcement providing clinical trial results and plans for regulatory filings, rather than a full financial report or earnings release. It does not contain detailed financial statements or management discussion of financial results. The document length is about 15,000 characters, which is typical for a regulatory announcement but not a full annual or quarterly report. Given these characteristics, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2010-06-03 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations release announcing the failure of a Phase III clinical trial for a drug (patupilone) and related information. There are no financial statements or detailed financial analysis present. The document is an announcement of clinical trial results and related corporate news rather than a financial report or regulatory filing with substantive financial data. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. Given the nature of the document as a regulatory filing providing corporate news and clinical trial update, the most appropriate classification is Regulatory Filings (RNS). The document length (8632 characters) is sufficient to contain substantive information but it is not a financial report. Therefore, the classification is RNS with high confidence.
2010-06-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.